Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy')

Toxicology Letters

Volumn 112-113, Issue , 2000, Pages 133-142

  Maurer, Hans H ^a   Bickeboeller Friedrich, Joerg ^a   Kraemer, Thomas ^a   Peters, Frank T ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Designer drugs; GC MS analysis; Metabolism; Methylenedioxy amphetamines; Toxicokinetics

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; DESIGNER DRUG; DRUG METABOLITE;

CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; TECHNIQUE; TOXICOKINETICS;

AMPHETAMINES; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; HUMANS; LIVER; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 0034653801     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00207-6     Document Type: Conference Paper

References (33)

1. Brunnenberg M., Lindenblatt H., Gouzoulis M.E., Kovar K.A. Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. J. Chromatogr. B. 719:1998;79-85.
2. Carvalho F., Remiao F., Amado F., Domingues P., Correia A.J., Bastos M.L. d-Amphetamine interaction with glutathione in freshly isolated rat hepatocytes. Chem. Res. Toxicol. 9:1996;1031-1036.
3. Chu T., Kumagai Y., Distefano E.W., Cho A.K. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem. Pharmacol. 51:1996;789-796.
4. Cody J.T. Detection of D,L-amphetamine, D,L-methamphetamine, and illicit amphetamine analogs using diagnostic products corporation's amphetamine and methamphetamine radioimmunoassay. J. Anal. Toxicol. 14:1990;321-324.
5. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115:1995;1281-1289.
6. Coutts R.T., Su P., Baker G.B. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Methods. 31:1994;177-186.
7. de-la-Torre R., Ortuno J., Farre M., Mas M., Rosert P.N., Menoyo E., Segura J. Pharmacokinetics of ecstasy (MDMA) in healthy subjects. Ther. Drug Monit. 19:1997;585.
8. Ensslin H.K., Kovar K.A., Maurer H.H. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, 'Eve') and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B. 683:1996;189-197.
9. Ensslin H.K., Maurer H.H., Gouzoulis E., Hermle L., Kovar K.A. Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab. Dispos. 24:1996;813-820.
10. Gouzoulis E., Steiger A., Ensslin M., Kovar A., Hermle L. Sleep EEG effects of 3,4-methylenedioxyethamphetamine (MDE; 'Eve') in healthy volunteers. Biol. Psychiatry. 32:1992;1108-1117.
11. Hegadoren K.M., Baker G.B., Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci. Biobehav. Rev. 23:1999;539-553.
12. Helmlin H.J., Bracher K., Bourquin D., Vonlanthen D., Brenneisen R. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS [see comments]. J. Anal. Toxicol. 20:1996;432-440.
13. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254:1990;521-527.
14. Jones A.L., Simpson K.J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 13:1999;129-133.
15. Kintz P. Excretion of MBDB and BDB in urine, saliva, and sweat following single oral administration. J. Anal. Toxicol. 21:1997;570-575.
16. Kraemer T., Maurer H.H. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine [review]. J. Chromatogr. B. 713:1998;163-187.
17. Kraemer T., Vernaleken I., Maurer H.H. Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B. 702:1997;93-102.
18. Kraemer, T., Bickeboeller-Friedrich, J., Maurer, H.H., 2000. On the metabolism of the amphetamine-derived antispasmodic drug mebeverine-GC-MS studies on rat liver microsomes and on human urine. Drug Metab. Dispos. (in press).
19. Kumagai Y., Lin L.Y., Schmitz D.A., Cho A.K. Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem. Res. Toxicol. 4:1991;330-334.
20. Kunsman G.W., Manno J.E., Cockerham K.R., Manno B.R. Application of the Syva EMIT and Abbott TDx amphetamine immunoassays to the detection of 3,4-methylene-dioxymethamphetamine (MDMA) and 3,4-methylene-dioxyethamphetamine (MDEA) in urine. J. Anal. Toxicol. 14:1990;149-153.
21. Lavigne J.A., Helzlsouer K.J., Huang H.Y., Strickland P.T., Bell D.A., Selmin O., Watson M.A., Hoffman S., Comstock G.W., Yager J.D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 57:1997;5493-5497.
22. Liebich H.M., Forst C. Basic profiles of organic acids in urine. J. Chromatogr. 525:1990;1-14.
23. Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., Tucker G.T., Cho A.K. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25:1997;1059-1064.
24. Maurer H.H. Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry [review]. J. Chromatogr. 580:1992;3-41.
25. Maurer H.H. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 18:1996;465-470.
26. Maurer H.H. Methods for GC-MS. Pfleger K., Maurer H.H., Weber A. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 3rd edition:1999;Wiley-VCH, Weinheim.
27. Maurer H.H., Arlt J.W., Kraemer T., Schmitt C.J., Weber A.A. Analytical development for low molecular weight xenobiotic compounds. Arch. Toxicol. 19(Suppl.):1997;189-197.
28. Moeller M.R., Hartung M. Ecstasy and related substances - serum levels in impaired drivers [letter; comment]. J. Anal. Toxicol. 21:1997;591.
29. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs. 18:1986;305-313.
30. Pfleger K., Maurer H.H., Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 3rd edition:1999;Hewlett Packard, Palo Alto (CA).
31. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y. The demethylenation of methylenedioxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47:1994;1151-1156.
32. Walubo A., Seger D. Fatal multi-organ failure after suicidal overdose with MDMA, 'ecstasy': case report and review of the literature. Hum. Exp. Toxicol. 18:1999;119-125.
33. Wu D., Otton S.V., Inaba T., Kalow W., Sellers E.M. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53:1997;1605-1612.